HomeREGULATORY
REGULATORY

MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
(Jul.3.2018)

Japan’s health ministry approved a throng of new medicines on July 2, with Takeda Pharmaceutical earning the OK for its Entyvio (vedolizumab) ulcerative colitis (UC) drug, and AstraZeneca notching two big wins with its cancer drugs Imfinzi (durvalumab) and Lynparza (olaparib) ...
(LOG IN FOR FULL STORY)